Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Cagrilintide Mechanism of Action
The Complete Journey: From Injection to Results
Cagrilintide is a long-acting amylin receptor agonist that activates amylin receptors in the brain and gastrointestinal tract. Amylin is naturally co-secreted with insulin from pancreatic beta cells and plays a crucial role in appetite regulation and glucose homeostasis. By activating amylin receptors in the area postrema and nucleus tractus solitarius of the brainstem, cagrilintide provides potent appetite suppression. It also slows gastric emptying, reduces glucagon secretion, and enhances insulin sensitivity, complementing GLP-1 pathway activation.
The Injection
You inject Cagrilintide under your skin. The amylin analog begins absorbing into your bloodstream.
Amylin Receptor Targeting
Cagrilintide travels to amylin receptors in your brain (particularly the brainstem) and stomach. These receptors control satiety and gastric emptying.
Gastric Slowing
The peptide dramatically slows gastric emptying, keeping food in your stomach longer. This creates stronger and longer-lasting satiety signals.
Appetite Suppression
Strong amylin receptor activation creates powerful appetite suppression. Your brain receives consistent 'full' signals, dramatically reducing food cravings.
Metabolic Adaptation
Your body adapts to the new eating pattern. Caloric intake reduces naturally without feeling deprived, leading to steady weight loss.
Sustained Results
Consistent appetite control leads to steady, sustainable weight loss. Body composition improves with preserved muscle mass.
How Cagrilintide Works at the Molecular Level
Scientific Mechanism
Cagrilintide is a long-acting amylin receptor agonist that activates amylin receptors in the brain and gastrointestinal tract. Amylin is naturally co-secreted with insulin from pancreatic beta cells and plays a crucial role in appetite regulation and glucose homeostasis. By activating amylin receptors in the area postrema and nucleus tractus solitarius of the brainstem, cagrilintide provides potent appetite suppression. It also slows gastric emptying, reduces glucagon secretion, and enhances insulin sensitivity, complementing GLP-1 pathway activation.
Simple Explanation
Think of Cagrilintide as working on a different pathway than most weight loss medications. While drugs like semaglutide work on the GLP-1 pathway, Cagrilintide works on the amylin pathway - another natural hormone system your body uses to control appetite and blood sugar. It's like having two different volume controls for hunger: one turns down appetite in your brain, and the other slows down how fast food leaves your stomach, keeping you full longer.
The Simple Truth: Why It Works So Well
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.